# Terbinafine HCl 250 mg Tablet Under Fasting Conditions

> **NCT00833586** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Terbinafine HCl 250mg tablets
- **DRUG:** Lamisil® 250 mg Tablets

## Key facts

- **NCT ID:** NCT00833586
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833586, "Terbinafine HCl 250 mg Tablet Under Fasting Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00833586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*